Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study

Psychiatry and Clinical Neurosciences

Volumn 61, Issue 6, 2007, Pages 622-629

  Rocca, Paola ^a   Marino, Federica ^a   Montemagni, Cristiana ^a   Perrone, Davide ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's disease; Behavioral disturbances; Olanzapine; Quetiapine; Risperidone

Indexed keywords

DONEPEZIL; GALANTAMINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

AGED; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; COGNITION; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; GAIT DISORDER; HALLUCINATION; HUMAN; INCIDENCE; INJURY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREDICTION; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; TIME SERIES ANALYSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT GAIN;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BEHAVIOR; BENZODIAZEPINES; COGNITION; DATA INTERPRETATION, STATISTICAL; DIBENZOTHIAZEPINES; ENDPOINT DETERMINATION; FEMALE; GALANTAMINE; HUMANS; INDANS; LONG-TERM CARE; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME;

EID: 36849006030     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2007.01729.x     Document Type: Article

References (31)

1. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int. J. Geriatr. Psychiatry 2000 15 (Suppl. 1 2 4.
2. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J. Am. Geriatr. Soc. 1990 38 : 553 563.
3. Jeste DV, Krull AJ, Kilbourn K. Tardive dyskinesia: Managing a common neuroleptic side effect. Geriatrics 1990 45 : 49 54.
4. Lawlor BA. Behavioral and psychological symptoms in dementia: The role of atypical antipsychotics. J. Clin. Psychiatry 2004 65 (Suppl. 11 5 10.
5. Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience. Drugs Aging 2002 19 : 257 276.
6. Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003 28 (Suppl. 1 39 51.
7. Tariot PN, Profenno LA, Isamail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J. Clin. Psychiatry 2004 65 (Suppl. 11 11 15.
8. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J. Am. Geriatr. Soc. 2006 54 : 354 361.
9. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J. Clin. Psychiatry 2003 64 : 726 730.
10. Gareri P, Cotroneo A, Lacava R et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch. Gerontol. Geriatr. 2004 9 : 207 215.
11. Deberdt WG, Dysken MW, Rappaport SA et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am. J. Geriatr. Psychiatry 2005 13 : 722 730.
12. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 2006 355 : 1525 1538.
13. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drugs treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005 294 : 1934 1943.
14. Gill SS, Rochon PA, Hermann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ 2005 330 : 445 450.
15. Caltagirone C, Bianchetti A, Di Luca M et al. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005 22 (Suppl. 1 1 26.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. American Psychiatric Association, Washington, DC, 2000.
18. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients by the clinician. J. Psychiatr. Res. 1975 12 : 189 198.
19. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the age. The index of ADL: A standardized measure of biological and psychological function. JAMA 1963 185 : 914 919.
20. Lowton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969 9 : 179 186.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994 44 : 2308 2314.
22. Ott BR, Fogel BS. Measurement of depression in dementia: Self vs. clinician rating. Int. J. Geriatr. Psychiatry 1992 7 : 899 904.
23. Ott BR, Lafleche G, Whelihan WM, Buongiorno GW, Albert MS, Fogel BS. Impaired awareness of deficits in Alzheimer's disease. Alzheimer Dis. Assoc. 1996 10 : 68 76.
24. Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 1997 48 (Suppl. 6 10 16.
25. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D. Treatment of agitation in older persons with dementia. Postgrad. Med. 1998 Special No. : 1 88.
26. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 2006 14 : 191 210.
27. Ellingrod VL, Schulz SK, Ekstam-Smith K, Kutscher E, Turvey C, Arndt S. Comparison of risperidone with olan zapine in elderly patients with dementia and psychosis. Pharmacotherapy 2002 22 : 1 5.
28. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of dementia. Psychoneuroendocrinology 2003 28 : 9 26.
29. Marder SR. Subjective experiences on antipsychotic medications: Synthesis and conclusions. Acta Psychiatr. Scand. 2005 427 : 43 46.
30. Ballard C, Margallo-Lano M, Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomized double blind placebo controlled trial. BMJ 2005 330 : 874 878.
31. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003 289 : 210 216.